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Background: In The Netherlands, helmet therapy is a commonly used treatment in infants with skull deformation
(deformational plagiocephaly or deformational brachycephaly). However, evidence of the effectiveness of this
treatment remains lacking. The HEADS study (HElmet therapy Assessment in Deformed Skulls) aims to determine
the effects and costs of helmet therapy compared to no helmet therapy in infants with moderate to severe skull
deformation.
Methods/design: Pragmatic randomised controlled trial (RCT) nested in a cohort study. The cohort study included
infants with a positional preference and/or skull deformation at two to four months (first assessment). At 5 months
of age, all children were assessed again and infants meeting the criteria for helmet therapy were asked to
participate in the RCT. Participants were randomly allocated to either helmet therapy or no helmet therapy. Parents
of eligible infants that do not agree with enrolment in the RCT were invited to stay enrolled for follow up in a
non-randomisedrandomised controlled trial (nRCT); they were then free to make the decision to start helmet
therapy or not. Follow-up assessments took place at 8, 12 and 24 months of age. The main outcome will be head
shape at 24 months that is measured using plagiocephalometry. Secondary outcomes will be satisfaction of parents
and professionals with the appearance of the child, parental concerns about the future, anxiety level and
satisfaction with the treatment, motor development and quality of life of the infant. Finally, compliance and costs
will also be determined.
Discussion: HEADS will be the first study presenting data from an RCT on the effectiveness of helmet therapy.
Outcomes will be important for affected children and their parents, health care professionals and future treatment
policies. Our findings are likely to influence the reimbursement policies of health insurance companies.
Besides these health outcomes, we will be able to address several methodological questions, e.g. do participants in
an RCT represent the eligible target population and do outcomes of the RCT differ from outcomes found in the
nRCT?
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Infants have malleable and fast-growing cranial bones, and
are therefore at risk of developing skull deformation if
their head often remains in the same position. When a
child turns its head toward one side most of the time, this
is defined as positional preference [1]. Skull deformation
due to such prolonged external forces (non-synostotic)
must be distinguished from skull malformation due to
premature fusion of the cranial sutures (synostotic) [2].
Deformational brachycephaly refers to a symmetric occipi-
tal flattening of the skull that is sometimes accompanied
by temporal bossing or an occipital lift [3]. The term de-
formational plagiocephaly is used to describe a unilateral
occipital flattening of the skull. More severe cases often
present with ear misalignment and facial asymmetry [2,4].
Skull deformation is generally considered a purely cos-
metic disorder. Yet parents worry that the deformation
might be permanent and might influence the child’s attract-
iveness with the risk of, for example, being teased [5]. Some
studies suggest long-term developmental delays due to skull
deformity, but no causal relationships have been found [5-7].
The prevalence of skull deformation can be up to 21.5%
in infants younger than 6 months, but decreases within the
first years of life [8-10]. A low parental level of education,
ethnicity, male gender, primiparity, prematurity, birth fac-
tors, delayed (motor) development, low activity level and
several positioning and dietary factors have been reported
as risk factors, while placing a child in the prone position
when awake appears to be a protective factor [1,11-17].
Prevention or treatment of positional preference and
skull deformation include parental counselling, counter-
positioning and physical therapy [10,18]. Children with
persisting severe skull deformation at the age of 5 to
6 months are commonly treated using orthotic devices
(redression helmets or headbands) [4,19]. In The Neth-
erlands, a redression helmet costs about €1,200 and is
reimbursed by health insurance companies as well as the
accompanying visits to the (paediatric) physician. How-
ever, until now, no randomised controlled trials (RCTs)
have been performed to study the effectiveness of this
therapy [20,21]. The few non-randomised studies tend
to show positive results, but have several limitations. To
start with it is unknown whether the reported differ-
ences in effectiveness are clinically relevant. Further-
more, follow-up in these studies was short-term (either
directly after treatment or just a few months afterwards),
there was a lack of blinding or information about blind-
ing and often no validated outcome measures were used.
Finally, data about complications were not collected in a
structural way in these studies [2,4,20,22,23]. Although
the known complications of helmet therapy are mild and
do not seem to occur often, the treatment burdens both
parents and their young children [22]. Next to the lack
of scientific evidence, experience shows differences inbeliefs and referral policies of health care professionals
regarding helmet therapy. Some advocate the use of hel-
mets to treat skull deformation, while others are reluc-
tant to prescribe this intensive treatment for a cosmetic
condition without knowing its effectiveness [21,24]. This
makes parents very uncertain when they have to decide
whether to start helmet therapy or not.
Both helmet therapy and no helmet therapy (allowing
natural recovery) are standard approaches in The Neth-
erlands. To compare the effectiveness of these two
approaches a pragmatic RCT study design is required
[25]. Pragmatic trials are designed to find out the effect-
iveness of a treatment in routine, everyday practice and
thereby have a high external validity [26,27]. A high ex-
ternal validity can be achieved by recruiting a broad
study population that is representative of the target
population, studying interventions that approach a real
world delivery of care, applying blinding to neither parti-
cipants nor specialists and selecting a wide range of out-
come measures [28,29].
Since the condition of interest changes over time and
the decision-making is time-dependent, the RCT needs to
be nested in a cohort study [30-32]. The decision to start
helmet therapy is usually taken at 5 to 6 months of age.
Recruitment at that stage is complicated as the children
tend to be scattered among various institutes if their par-
ents prefer helmet therapy or are outside the health care
system if their parents choose not to start helmet therapy.
As the cohort study recruits children at risk of disease
progression before helmet therapy can be prescribed, we
tackle this problem and we are also able to predict the
number of children that ultimately will be eligible for hel-
met therapy and identify prognostic factors.
Additionally, nesting the RCT in a prospective cohort
study makes it possible to present information on the
representativeness of the RCT population, by comparing
this population with non-participants [33,34]. Further-
more, outcomes of the randomised trial can be com-
pared with the parallel non-randomised trial that
employs the same types of intervention.
The main goal of the Helmet Therapy Assessment in
Deformed Skulls (HEADS) study is to investigate the
effects and costs of six months of helmet therapy com-
pared to no helmet therapy in children with moderate to
severe skull deformation. This article describes how this
study is designed and reports the recruitment scheme so
far. We provide a description of the statistical analysis plan
to be used after data collection is completed and conclude
with general recommendations on study design.
Methods/design
Study design
The HEADS study is a two-armed pragmatic RCT nested
in a cohort study (Figure 1). The intervention is redression
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(allowing natural recovery). The study starts as a cohort
study for children aged two to four months with a pos-
itional preference and/or skull deformation (T0). At five
months of age (T5), follow-up assessments are performed
and parents of children with a moderate to severe skull
deformation are invited to participate in the RCT. Eligible
children whose parents do not wish to enrol in the RCT
are invited to join the non-randomised controlled trial
(nRCT) that runs parallel to the RCT. In both studies,
follow-up assessments are performed at eight (T8), twelve
(T12) and twenty-four months (T24) of age.
Ethics approval for the study was given on the 8th
January 2009 (ref: NL24352.044.08) by the Medical Eth-
ics Committee of the Medisch Spectrum Twente hos-
pital in Enschede, The Netherlands.
Recruitment & setting
Participants were recruited (April 2009 to present) and
measured by specially trained paediatric physical thera-
pists (HEADS PPTs) in the Eastern part of the Nether-
lands (in the provinces of Drenthe, Overijssel and parts
of Gelderland).Figure 1 Flow chart of participants in HEADS. Provisional data.In The Netherlands, all infants are screened in the first
months of life for positional preference and skull de-
formation at well-baby clinics. Youth Health Care pro-
fessionals working at well-baby clinics in the region
where the study is carried out have been informed about
this study, reminded to look for this condition and asked
to refer cases to HEADS PPTs.
There are 96 HEADS PPTs involved in the study,
working in 73 physical therapist practices. They all
received three instruction sessions from the researchers
of the HEADS study, including theory lessons on pos-
itional preference and skull deformation, a refresher
course about plagiocephalometry (PCM) assessment and
training in recruiting patients for RCTs.
Based on their experience and performance in the
HEADS study, six HEADS PPTs were selected to per-
form the assessments at T24 (T24-HEADS PPTs) and
received an extra instruction session.
Children could be treated with helmet therapy at Pro-
Reva (Zwolle), Deventer Hospital/LIVIT (Deventer) and
Slingeland Hospital/Roessingh Rehabilitation Technique
(Doetinchem). At the start of the HEADS study, these
were the only institutions providing helmet therapy
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therefore they were asked to collaborate in the RCT.
Parents of children in the nRCT could also choose insti-
tutions outside of this region or newer institutes that
provide helmet therapy within the region.
Eligibility criteria
Cohort study
Children aged two to four months with a positional pre-
ference and/or skull deformation are eligible for the co-
hort study. Premature children (gestational age below
36 weeks), children with congenital muscular torticollis,
craniosynostosis and/or dysmorphic features are all
excluded.
Randomised controlled trial
Children aged 5 months with a moderate to severe skull
deformation, measured by PCM are eligible for the RCT.
PCM is a reliable, valid, non-invasive and easy-to-use
method for measuring the shape of the skull [35,36]. To
determine the severity of deformational plagiocephaly,
the oblique diameter difference index (ODDI) is used.
This is the ratio between the longest and the shortest
oblique diameter, multiplied by 100%. Both diameters
are located at 40° from the anterior-posterior line. A
moderate to severe plagiocephaly is defined as
108% ≤ODDI ≤ 113%. The severity of deformational bra-
chycephaly is established with the cranio proportional
index (CPI). This is the ratio between the width and the
length of the skull and is considered to be moderate to
severe when 95% ≤CPI ≤ 104%. Mixed forms with ODDI
> 106% and CPI> 92% are also included. Exclusion cri-
teria are similar to those at T0.
At T5, children meeting RCT eligibility criteria can
still enrol in the study (late-enrolment).
Non-randomised controlled trial
Children eligible for the RCT, but whose parents
declined participation, are invited to participate in the
nRCT for follow-up. Children with PCM outcomes
above the upper thresholds of the inclusion criteria for
the RCT are also asked to participate in the nRCT.
Population
Figure 1 shows that 883 infants enrolled at T0 for base-
line measurement. At T5, 808 infants had a follow-up
assessment; 477 did not meet the inclusion criteria for
the RCT. Of these 477 infants, 26 infants had PCM out-
comes above the upper thresholds of the inclusion cri-
teria for the RCT and were eligible to participate in the
nRCT. Seventy-five infants enrolled at T5 via late-
enrolment, of whom 5 infants had PCM outcomes above
the upper thresholds of the inclusion criteria for the
RCT and were eligible to participate in the nRCT. Of theeligible 401 infants, 84 (21%) were recruited for the
RCT, 296 did not participate in the RCT because their
parents declined to enrol them, but were recruited for
the nRCT (74%) and 21 (5%) were not recruited to ei-
ther of the studies. Parents signed an informed consent
form before participation in the cohort study, as well as
before participation in the RCT.Randomisation
A computer-generated blocked randomisation plan with
blocks of eight participants is used to allocate treatment
in the RCT. After a HEADS PPT enrols a child for the
RCT, he or she informs the researcher (RMW) who con-
tacts the parents. Both parents and researcher are un-
aware of allocation until the parents have signed the
informed consent form and confirmed participation. The
researcher performs the allocation and informs the par-
ents about group allocation. The child’s HEADS PPT,
general practitioner and Youth Health Care professional
are also informed about the allocation afterwards.Blinding
Blinding of parents and professionals to allocation is not
possible during the intervention period, including the T8
and T12 assessment. To ensure unbiased long-term out-
comes, the T24 assessments are blinded. These assess-
ments are carried out by T24-HEADS PPTs, who are
unfamiliar with the history of the infants they are meas-
uring. Furthermore, we instruct parents in the invitation
letter and a poster at the assessment location, not to
mention group allocation to the assessor.Interventions
Randomised controlled trial
Helmet therapy: parents of participants allocated to the
helmet therapy group were asked to make an appoint-
ment at one of the three collaborating institutes for hel-
met therapy. First a (paediatric) physician was consulted
to confirm diagnosis and exclude contraindications. Sub-
sequently, the orthotist provided care as usual; he con-
structed the custom-made helmet, supplied information
about introducing the helmet to the infant, regular wear-
ing instructions and instructions about cleaning of the
helmet and general care. The helmet has to be worn for
at least 23 hours per day from six to twelve months of
age.
No helmet therapy: Parents of participants allocated to
the no helmet therapy group were asked not to start any
treatment for the skull deformation of their child. In this
group, recovery of deformation of the head was awaited
by allowing spontaneous growth of the skull.
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In the nRCT, parents were able to select a treatment for
their child, that is, either helmet therapy or no helmet
therapy. The choice was recorded afterwards when the
child was twelve months old (T12).
Data collection
The cohort study started with a baseline measurement
at two to four months of age (T0). A follow-up measure-
ment was performed in all children at 5 months of age
(T5).
In the RCT, assessments took place at the age of
8 months (T8), 12 months (T12) and 24 months (T24)
(Figure 1). In the nRCT the same assessments took place
at T12 and T24. At T8 only a parental questionnaire
was collected by mail.
Data were collected by the HEADS PPTs. During every
assessment, the shape of the skull was measured, a
motor assessment was carried out and both the parents
and the HEADS PPTs were asked to complete a ques-
tionnaire. The HEADS PPT sent the data about each
child to the researcher (RMW).
Baseline characteristics
Through the parental questionnaire at T0 and the paren-
tal questionnaire for late-enrolment at T5, information
about background characteristics, medical characteristics
and other possible prognostic factors were collected.
Primary outcome
The primary outcome is the transverse shape of the skull
at 24 months, measured with PCM. The severity of de-
formational plagiocephaly was determined using the
ODDI, and ear deviation (ED) was calculated to deter-
mine ear misalignment. The severity of deformational
brachycephaly was determined by the CPI. A continuous
outcome variable (change in score from pre- to post-test
) as well as a dichotomous outcome variable will be used
for analysis. The dichotomous variable distinguishes full
recovery from no full recovery with a cut-off for full re-
covery of ODDI< 104% and CPI< 90%.
Secondary outcomes
Secondary outcomes are 1) satisfaction of the parents and
HEADS PPT with skull shape, face and body (5-point
Likert scale); 2) psychomotor development (a modified
Gesell assessment, at regular well-baby clinic visits) [37];
3) motor domain of Bayley Scales of Infant Development
(BSID III) [38]; 4) anxiety level of parents (Spielberger
State-Trait Anxiety Inventory, Dutch version) [39]; 5)
parental concerns about the child’s future, possible teas-
ing and uncertainty about the child’s appearance (5-point
Likert scale); 6) quality of life (Infant Toddler Quality ofLife Questionnaire (ITQOL-SF47) [40]) and 7) parental
satisfaction with treatment.Compliance
The questionnaire at T12 assessed whether parents were
compliant with the therapy to which their child was
assigned. Also recorded, was whether parents switched
groups, and if they did, the age this happened and the
reason for it. The helmet providers also collected start
and end dates of helmet therapy given to infants in the
RCT. Furthermore, helmets in the RCT of the HEADS
study are equipped with a logging device (LoD). The
LoD measures the number of hours a helmet is worn
per week (therapy compliance) and will be used to deter-
mine a dose–response relationship. The LoD was
attached to the helmet and data were sent to the re-
searcher after the invention period.
In both groups, parents were asked at T12 whether
they provided extra care to treat the skull deformation
of their child, such as the use of positioning devices, per-
forming exercises with their child or applying various
additional therapies.Determination of costs
Cost data were collected alongside the effectiveness
study. Both medical costs and indirect costs incurred by
parents because of diagnostic work-up and treatment
were recorded. Indirect costs were collected with the
help of a diary completed by parents during the inter-
vention period. Costs are being determined for both the
RCT and the nRCT.Sample size
The required sample size for the HEADS RCT, based on
a significance level of 5%, power of 90% and a difference
in mean improvement of at least 4 ODDI-points (SD 6
ODDI-points) was calculated as 72 infants (36 in each
arm). Assuming a maximum estimated loss-to-follow up
of 25%, we needed to include 96 children in the RCT.
In 2008, a preliminary study was performed into the
feasibility of an RCT on helmet therapy for skull de-
formation. Of the parents of 61 children with a skull de-
formation, 39% agreed to participate in a study as
described in the patient information and verbally clari-
fied. In the light of this information, the size of the
current study region was chosen and the inclusion
period was estimated.Statistical analyses
Data analyses will be performed using SPSS 18.0. A stat-
istical significance level of 0.05 will be used and missing
values will be imputed with multiple imputation [41].
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Data analysis will start with descriptive statistics of base-
line demographic and clinical characteristics of the total
population at T0. At T5, this will be repeated for the
clinical characteristics.
Randomised controlled trial
At T5, characteristics of the RCT population will be
described. In a subsequent analysis, the intervention and
control group will be compared with respect to prognos-
tic factors using the independent samples t-test or the
chi square test. The representativeness of the RCT
population will be determined by comparing baseline
demographic and clinical characteristics of the RCT
population with those of the total eligible population at
T5. Both the change score (continuous variable) and the
success of recovery (dichotomous variable) will be com-
pared between groups on an intention-to-treat basis.
After analysis of covariance (ANCOVA), both multiple
regression analyses (change score) and logistic regression
analyses (success of recovery) will be carried out with
predictor variables to control for confounders. Finally, a
per-protocol analysis will be performed.
Non-randomised controlled trial
Baseline characteristics and applied therapies will be
described for participants in the nRCT and compared
between children treated with a helmet and children
whose parents chose not to start helmet therapy. Simi-
larly to the RCT, both the continuous and the dichotom-
ous variables will be compared between groups on an
intention-to-treat basis. After univariate analyses, both
multivariate and logistic regression analyses will be car-
ried out adding predictor variables.
Comparison between the randomized and the
non-randomised controlled trials
Baseline characteristics will be compared between the
RCT and the nRCT. To study differences in the continu-
ous as well as the dichotomous variable between the
RCT and the nRCT, both a multiple linear regression
analysis and a logistic regression analysis will be carried
out, with the interaction factor of study (RCT or nRCT)
× group (helmet or no helmet).
Discussion
The HEADS trial is the first study to present an RCT on
the long-term effects of helmet therapy compared to no
helmet therapy in infants with moderate to severe skull
deformation. The HEADS study started as a cohort
study for infants aged two to four months, and contin-
ued as an RCT after the first follow-up assessment at the
age of five months. In parallel with the RCT, a non-
randomised controlled trial (nRCT) was carried out.This extensive cohort study will provide excellent oppor-
tunities to study the determinants of skull deformation.
Outcomes of the RCT and the nRCT will provide object-
ive information about treatment options for the parents
of affected children. With this information, an informed
decision can be made whether to start helmet therapy or
not. Additionally, outcomes from the cost-effectiveness
study are expected to influence future treatment and re-
imbursement policies.
Recruitment in RCTs is often a challenge and it is
common that trials fail to reach their target sample size
[42]. In the RCT of the HEADS study, enrolment also
proved more difficult than expected. During the recruit-
ment period, it gradually became clear that only 21% of
the parents of eligible infants gave consent for the RCT
(Figure 1). This is half of the 39% enrolment rate pre-
dicted in the preliminary study, and questions the valid-
ity of a preliminary study. A much longer recruitment
period is needed to recruit the calculated sample size of
96, necessary in case of a maximal loss to follow-up of
25%.
However, most parents refusing participation in the
RCT are willing to enrol in the nRCT. Figure 1 shows
that only 21 participants who were eligible for participa-
tion in the RCT or nRCT were not recruited, implying
that almost the complete group of eligible patients at T5
(n = 331) from the original cohort was followed in the
HEADS study. This emphasizes the advantage of the
nested RCT design; due to their participation in the co-
hort study, participants are already committed to the
study once the RCT and nRCT recruitment starts.
Another methodological advantage of the present
study design is its ability to better evaluate the represen-
tativeness of the RCT study population. Usually, RCTs
have homogeneous yet very selective populations to
maximize the likelihood of detecting significant differ-
ences. The cohort study of the HEADS study represents
a broad population. Due to the nested study design, it is
possible to determine the external validity of the RCT,
by testing whether the RCT population is representative
of the broad, eligible population at T5. The same can be
determined for the nRCT population. Furthermore, we
can study whether participants in the RCT are compar-
able to the nRCT participants by comparing the study
outcomes and baseline characteristics in both studies.
Finally, as the decision for helmet therapy in the nRCT
group was made by parents themselves, this will allow
us to investigate the relationship between real-world
decisions and treatment outcomes. This provides more
information on the usefulness of data from non-
randomised compared to randomised studies, which is
relevant in comparative effectiveness research. Further-
more simultaneous analysis of data from an RCT and
nRCT can strongly contribute to the generalizability of
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practice guidelines as compared to single RCTs [43].
Final results of the HEADS study are expected in 2013.
Trial status
The trial is ongoing.
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